Hypera (HYPE3) investor relations material

Executive summary

• Net revenue grew 86.7% year-over-year to R$2,017.8 million in Q1 2026, driven by 9.4–9.5% sell-out growth and market share gains in key categories, supported by new product launches and enhanced marketing investments.

• EBITDA from continuing operations reached R$586.5 million (29.1% margin), reversing a negative EBITDA in Q1 2025 and reflecting operational recovery post working capital optimization.

• Net income from continuing operations was R$345.7 million, a significant turnaround from a loss in Q1 2025.

• Successfully completed a R$1.5 billion capital increase, strengthening the balance sheet, reducing net debt by 17.8–20%, and enhancing liquidity and investment capacity.

• Improved logistics efficiency, with OTIF up 12 percentage points and order cycle time down 14% year-over-year.

Financial highlights

• Net revenue: R$2,017.8 million in Q1 2026, an 86.7% increase year-over-year.

• EBITDA: R$586.5 million, with a margin of 29.1%.

• Gross margin: 60.0%, up 1,280 basis points year-over-year, impacted by plant idleness and collective vacations.

• Net income from continuing operations: R$345.7 million, up from a loss in Q1 2025.

• Free cash flow after investments: R$367.8 million, up 5.6% year-over-year.

Outlook and guidance

• Expectation for sell-out growth to remain at the upper end of the anticipated range, with positive trends continuing into April.

• Management reaffirmed projections for increased operational cash generation from working capital optimization, targeting R$2.5 billion by 2028 and R$7.5 billion over 10 years.

• New launches projected to contribute up to 2.63 percentage points to sell-out growth in 2026, with expansion into diabetes and testosterone/weight-loss markets.

• Anticipate normalization of plant idleness and further inventory reductions starting in Q2.

• Capital structure improvements and deleveraging enhance resilience against credit market volatility, especially in an election year.